Arcturus Therapeutics Holdings Inc - Company Profile
Powered by 
All the data and insights you need on Arcturus Therapeutics Holdings Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Arcturus Therapeutics Holdings Inc Strategy Report
- Understand Arcturus Therapeutics Holdings Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Arcturus Therapeutics Holdings Inc (Arcturus Therapeutics) is a biotechnology company that develops messenger RNA (mRNA) medicines. It focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases and rare diseases. The company's major products include a lipid nanoparticle (LNP) delivery system, LUNAR, and mRNA technology. Its pipeline product portfolio includes ARCT-810 (LUNAR-OTC) and ARCT-032 (LUNAR-CF). LUNAR-CF is a grant program with the Cystic Fibrosis Foundation to treat cystic fibrosis using mRNA therapies. The company provides mRNA that is used as protein replacement therapy to treat diseases caused by a lack of protein or defective proteins, such as cystic fibrosis. Arcturus Therapeutics Inc is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
10628 Science Center Dr Ste 250, San Diego, California, 92121-1132
Website
arcturusrx.com
Telephone
1 858 9002660
No of Employees
180
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ARCT (NASD)
Revenue (2022)
$166.8M
-19%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-417.9%
(2022 vs 2021)
Market Cap*
$821.3M
Net Profit Margin (2022)
XYZ
-492.5%
(2022 vs 2021)
* As of and is in US$
Arcturus Therapeutics Holdings Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Pipeline | Service: | STARR |
| ARCT-810 (LUNAR-OTC) | Contract Drug Manufacturing Organization (CDMO) | LUNAR |
| ARCT-032 (LUNAR-CF) | ||
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In February, the company received Orphan Medicinal Product Designation from the European Commission (EC), for the treatment of cystic fibrosis. |
| 2024 | Contracts/Agreements | In January, the company announced a collaboration with PassPort Technologies to analyze innovative mRNA formulations and transdermal delivery mechanisms for vaccines and therapeutics. |
| 2023 | Regulatory Approval | In November, the company received Orphan Drug Designation from the US Food and Drug Administration (FDA) for ARCT-032. |
Competitor Comparison
| Key Parameters | Arcturus Therapeutics Holdings Inc | Pfizer Inc | Sanofi | AstraZeneca Plc | Moderna Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | France | United Kingdom | United States of America |
| City | San Diego | New York | Paris | Cambridge | Cambridge |
| State/Province | California | New York | Ile-de-France | England | Massachusetts |
| No. of Employees | 180 | 88,000 | 87,994 | 89,900 | 5,600 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Peter Farrell | Chairman | Executive Board | 2018 | 81 |
| Joseph E. Payne | Director; President; Chief Executive Officer | Executive Board | 2013 | 52 |
| Andrew Sassine | Chief Financial Officer; Director | Executive Board | 2019 | 59 |
| Padmanabh Chivukula, Ph.D. | Chief Operating Officer; Chief Scientific Officer | Senior Management | 2013 | 45 |
| Lance Kurata | Chief Legal Officer | Senior Management | 2020 | 54 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer